Search
6-O-benzylguanine
go.drugbank.com/drugs/DB11919Investigational6-O-benzylguanine has been used in trials studying the treatment of HIV Infection, Adult Gliosarcoma, Adult Glioblastoma, Stage I Adult Hodgkin Lymphoma, and Stage II Adult Hodgkin Lymphoma, among others.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesSelinexor
go.drugbank.com/drugs/DB11942ApprovedInvestigationalSelinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. Selinexor, in combination with bortezomib and dexamethasone, is currently approved for the treatment of multiple myeloma, a type of cancer formed fro...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesDacomitinib
go.drugbank.com/drugs/DB11963ApprovedInvestigationalis an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor
Categories: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, P-glycoprotein inhibitorsSJG-136
go.drugbank.com/drugs/DB11965InvestigationalSJG-136 has been used in trials studying the treatment of Recurrent Fallopian Tube Cancer, Secondary Acute Myeloid Leukemia, de Novo Myelodysplastic Syndromes, Recurrent Ovarian Epithelial Cancer, and Secondary Myelodysplastic Syndromes,...
Categories: P-glycoprotein substratesBinimetinib
go.drugbank.com/drugs/DB11967ApprovedInvestigationalBinimetinib, also known as Mektovi, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with Encorafenib. On June 27, 2018, the Food and Drug Administration approved the combination o...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesPonesimod
go.drugbank.com/drugs/DB12016ApprovedInvestigationalPonesimod is a selective sphingosine 1-phosphate receptor 1 modulator indicated in the treatment of relapsing forms of multiple sclerosis in adults. … [A232079,L32709] Ponesimod was developed out of a need for a more selective modulator of sphingosine 1-phosphate receptor 1 than [fingolimod].
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesLorvotuzumab mertansine
go.drugbank.com/drugs/DB12089InvestigationalLorvotuzumab mertansine has been used in trials studying the treatment of SCLC, Leukemia, Ovarian Cancer, Multiple Myeloma, and Merkel Cell Carcinoma, among others.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsSecoisolariciresinol
go.drugbank.com/drugs/DB12179InvestigationalSecoisolariciresinol has been used in trials studying the prevention of Breast Cancer.
Categories: P-glycoprotein inhibitorsFexinidazole
go.drugbank.com/drugs/DB12265ApprovedHuman African trypanosomiasis (HAT, also colloquially referred to as sleeping sickness), caused by T. brucei gambiense and T. brucei rhodesiense, remains a moderate risk (>1/10,000 inhabitants per year in endemic areas) despite focuss...
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 SubstratesEpofolate
go.drugbank.com/drugs/DB12266InvestigationalEpofolate (BMS-753493) is a folate conjugate of the epothilone analog BMS-748285 that was designed to selectively target folate receptor expressing cancer cells.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors